Key result
After adjusting for inflation, the average Medicare reimbursement for 28 orthopaedic oncologic procedures decreased by 9.9% from 2002 to 2018.
Why the study?
Evaluating trends in procedure reimbursements is critical to assess and ensure financial stability in orthopaedic oncology as US healthcare shifts toward cost-containment and value-based care.
Observational
Medicare reimbursements for orthopaedic oncologic procedures have steadily decreased by an average of 9.9% from 2002 to 2018 after adjusting for inflation, highlighting potential financial stability concerns for the specialty.
May strain orthopaedic oncology finances; leaves open effects on access and specialty sustainability.
Background: As the United States (US) healthcare system evolves towards cost-containment and value-based approaches, evaluating trends in procedure reimbursements will be critical for assessing and ensuring financial stability of highly specialized fields, such as orthopaedic oncology. Methods: The Medicare Physician Fee Schedule (MPFS) look-up tool was accessed through the official Center for Medicaid and Medicare Services website and used to retrieve average reimbursement rates for 28 common orthopaedic oncologic procedures (radical resections of soft tumors, bone tumors, and prophylactic treatment, nailing, or pinning) from 2002 to 2018. All reimbursement data were adjusted for inflation to 2018 dollars. For each Current Procedural Terminology (CPT) code, average reimbursement percentage change from 2002 to 2018 was calculated. Results: Based on the included codes, physician payment data for 28 surgical procedures from 2002 to 2018 were retrieved from the MPFS database. After adjusting all data for inflation, the average reimbursement for all included procedures decreased by 9.9% from 2002 to 2018, representing an estimated average decrease of 1.1% every couple of years. Reimbursement percentage decreases were the most significant prior to the Medicare Access and CHIP Reauthorization Act (MACRA), with reimbursements decreasing by an average of 5.8% from 2002 to 2014. However, reimbursement rates still declined by an average of 4.3% from 2014 to 2018 (after MACRA). Discussion: Reimbursements for orthopaedic oncologic procedures have steadily decreased over time. With orthopaedic oncology being a highly specialized field with few practicing providers, health policy makers need to understand the financial implications of the declining reimbursement rates to ensure financial stability and viability of the specialty. Level of Evidence: Level III.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2022) conducted an observational in Orthopaedic oncology. Orthopaedic oncologic procedures was evaluated on Average reimbursement percentage change from 2002 to 2018. After adjusting for inflation, the average Medicare reimbursement for 28 orthopaedic oncologic procedures decreased by 9.9% from 2002 to 2018.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: